Paradigm Biopharmaceuticals Limited

ASX:PAR Stock Report

Market Cap: AU$148.2m

Paradigm Biopharmaceuticals Management

Management criteria checks 3/4

Paradigm Biopharmaceuticals' CEO is Paul Rennie, appointed in Jan 2014, has a tenure of 11.75 years. total yearly compensation is A$1.06M, comprised of 93.4% salary and 6.6% bonuses, including company stock and options. directly owns 2.27% of the company’s shares, worth A$3.36M. The average tenure of the management team and the board of directors is 5.2 years and 4.8 years respectively.

Key information

Paul Rennie

Chief executive officer

AU$1.1m

Total compensation

CEO salary percentage93.36%
CEO tenure11.8yrs
CEO ownership2.3%
Management average tenure5.2yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

We're Keeping An Eye On Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Rate

Apr 22
We're Keeping An Eye On Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Rate

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17
Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22
Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24
We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28
Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29
When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

CEO Compensation Analysis

How has Paul Rennie's remuneration changed compared to Paradigm Biopharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025AU$1mAU$988k

-AU$19m

Mar 31 2025n/an/a

-AU$17m

Dec 31 2024n/an/a

-AU$15m

Sep 30 2024n/an/a

-AU$37m

Jun 30 2024AU$1mAU$948k

-AU$59m

Mar 31 2024n/an/a

-AU$64m

Dec 31 2023n/an/a

-AU$70m

Sep 30 2023n/an/a

-AU$61m

Jun 30 2023AU$2mAU$602k

-AU$52m

Mar 31 2023n/an/a

-AU$48m

Dec 31 2022n/an/a

-AU$44m

Sep 30 2022n/an/a

-AU$42m

Jun 30 2022AU$1mAU$219k

-AU$39m

Mar 31 2022n/an/a

-AU$40m

Dec 31 2021n/an/a

-AU$41m

Sep 30 2021n/an/a

-AU$37m

Jun 30 2021AU$1mAU$510k

-AU$34m

Mar 31 2021n/an/a

-AU$31m

Dec 31 2020n/an/a

-AU$28m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$632kAU$462k

-AU$12m

Mar 31 2020n/an/a

-AU$14m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$16m

Jun 30 2019AU$1mAU$420k

-AU$16m

Compensation vs Market: Paul's total compensation ($USD699.13K) is above average for companies of similar size in the Australian market ($USD295.56K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Rennie (66 yo)

11.8yrs
Tenure
AU$1,058,547
Compensation

Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Rennie
Founder11.8yrsAU$1.06m2.27%
A$ 3.4m
Donna Skerrett
Chief Medical Officer3.3yrsAU$405.06k0.27%
A$ 393.9k
Abby Macnish Niven
Company Secretary & CFO3.2yrsno datano data
Ravi Krishnan
Chief Scientific Officer10.1yrsno datano data
Simon White
Director of Investor Relationsno datano datano data
Michael Imperiale
Global Head of Drug Safety & MPS5.3yrsno datano data
Beverley Huttmann
Commercial Head5yrsno datano data
Mukesh Ahuja
Global Clinical Head of OAno datano datano data
5.2yrs
Average Tenure
66yo
Average Age

Experienced Management: PAR's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Rennie
Founder11.4yrsAU$1.06m2.27%
A$ 3.4m
Amos Meltzer
Independent & Non-Executive Director4.8yrsAU$89.20kno data
Matthew Fry
Independent Non-Executive Director1.6yrsAU$80.00k0.34%
A$ 511.1k
4.8yrs
Average Tenure

Experienced Board: PAR's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/06 08:07
End of Day Share Price 2025/10/06 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Paradigm Biopharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Soo RomanoffEdison Investment Research
Arron AatkarEdison Investment Research